Variation of body regional responses to Ustekinumab and Secukinumab in psoriasis patients: A real‐world retrospective study and literature review
- 22 November 2022
- journal article
- research article
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 35 (12), e15950
- https://doi.org/10.1111/dth.15950
Abstract
Psoriasis in different body regions displays varying therapeutic responses to biologics, whereas currently relevant studies remain scarce. We retrospectively reviewed the treatment responses of patients with moderate-to-severe psoriasis, who completed the two-year reimbursed ustekinumab or secukinumab treatment in two medical centers in Southern Taiwan. Demographic profiles and body regional PASI scores (head/neck, trunk, upper and lower limbs) along the treatment course were recorded. The proportions of patients attaining PASI 75, 90, 100 and the extent of body regional PASI score improvements were compared in biologic naive or experienced patients. A total of 57 and 67 patients receiving ustekinumab and secukinumab injections, respectively, were included. Overall, patients receiving secukinumab showed higher degrees of PASI score improvements along the two-year treatment course. The lower limbs had the highest, and the upper extremities and head/neck had the lowest post-treatment PASI scores regardless of prior biologic use in the groups of ustekinumab and secukinumab. The upper limbs showed the highest, while the lower limbs had the lowest complete remission rate (regional specific PASI 100) in response to ustekinumab (upper limbs 48.7%, lower limbs 25.6%) and secukinumab (upper limbs 77.1%, lower limbs 42.8%) in biologic naive groups. Our study demonstrated that lower limbs were the most treatment-refractory area in response to ustekinumab and secukinumab injections, while the upper limbs and head/neck region had a better response.Keywords
Funding Information
- National Cheng Kung University Hospital (NCKUH‐11102028)
This publication has 14 references indexed in Scilit:
- Localization of treatment‐resistant areas in patients with psoriasis on biologicsBritish Journal of Dermatology, 2019
- Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studiesJournal of the American Academy of Dermatology, 2018
- Improvements in psoriasis within different body regions vary over time following treatment with ixekizumabJournal of Dermatological Treatment, 2017
- Evidence and suggested therapeutic approach in psoriasis of difficult-to-treat areas: Palmoplantar psoriasis, nail psoriasis, scalp psoriasis, and intertriginous psoriasisIndian Journal of Dermatology, 2017
- Body Region Involvement and Quality of Life in Psoriasis: Analysis of a Randomized Controlled Trial of AdalimumabAmerican Journal of Clinical Dermatology, 2016
- Efficacy of Secukinumab for Moderate-to-Severe Head and Neck Psoriasis Over 52 Weeks: Pooled Analysis of Four Phase 3 StudiesDermatology and Therapy, 2016
- Efficacy of Secukinumab on Moderate-to-severe Plaque Psoriasis Affecting Different Body Regions: a Pooled Analysis of Four Phase 3 StudiesDermatology and Therapy, 2016
- Clinical meaningfulness of complete skin clearance in psoriasisJournal of the American Academy of Dermatology, 2016
- Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical settingJournal of the American Academy of Dermatology, 2014
- Pattern of response in patients with moderate-to-severe psoriasis treated with etanerceptBritish Journal of Dermatology, 2014